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nor paracetamol or aspirin). There were a majority of “stoppers”
even among those who previously received celecoxib (53.4%).
The proportion of patients with long term COX-2 treatment (3
months or over) was higher in the “continuers” group (23.9%
vs. 13.7%; p < 0.001). Conversely, patients with history of stroke
(4.2% vs. 2.6%; p = 0.026) or coronary heart disease (14.7%
vs. 11.5%; p = 0.015) and with a higher risk of gastrointestinal
events (50.7% vs. 43.2%; p < 0.0001) were in greater propor-
tion in the “stoppers” group. Finally, the percentage of NSAID
treated patients receiving a proton pump inhibitor raised sub-
stantially from 37.1% to 72.0% (p < 0.001) between the two
periods. CONCLUSIONS: French GPs reacted in a non selective
way, making little difference between rofecoxib and celecoxib,
and between cardiovascular and gastrointestinal risks. This
unexpected behaviour may be interpreted as a concern toward a
reduction of any kind of risk and not only those targeted by the
withdrawal decision.
OA4
A HEALTH-ECONOMIC EVALUATION OF RHBMP-2 IN SPINE
FUSION SURGERY IN GERMANY AND UK
Chhabra A1, Bentley A2, Donnell D1, Greenberg D3, Oliver E4,Alt V5
1Medtronic Europe Sarl,Tolochenaz, Switzerland, 2Abacus
International, Bicester, UK, 3Ben-Gurion University of the Negev, Beer-
Sheva, Israel, 4Medtronic Ltd, Watford, UK, 5University Hospital
Giessen-Marburg, Brackenheim, Germany
OBJECTIVES: Chronic low-back pain related to osteoarthritic
changes of the lumbar spine has a signiﬁcant economic impact
on health care budgets worldwide. Anterior-Lumbar-Interbody-
Fusion (ALIF) surgery can be an effective treatment option after
non-operative therapy fails. Frequently, the affected vertebrae are
fused together using bone (autograft) from patient’s hip, which
requires additional surgery and leads to increased co-morbidity,
blood loss, infection rate, and pelvic instability. We assessed the
cost-effectiveness of rhBMP-2 compared with autograft in spine
fusion surgery over two years from a health care payer’s per-
spective in Germany and UK. METHODS: An economic model
was developed to evaluate differences in the two-year results
between spine-fusion surgery with rhBMP-2 and fusion with
bone autograft. The cost and health-related quality-of-life asso-
ciated with both arms were estimated for two years after surgery.
Data were obtained from a previously published analysis of
pooled data, in which patients in the rhBMP-2 arm showed sig-
niﬁcant clinical improvements after surgery compared to stan-
dard therapy. Cost data were obtained from German-DRGs 
and UK NHS and are reported in 2005 values. RESULTS: In
Germany, signiﬁcant reduction in secondary interventions, and
better fusion rates associated with rhBMP-2 treatment resulted
in faster return to work and generated savings of €3453 per
patient for health care insurances, leading to net savings of €503
per patient. These savings offset the upfront prize of €2950 for
rhBMP-2 therapy. In the UK, the beneﬁts of use of rhBMP-2 lead
to an incremental cost-effectiveness ratio of GBP 5483/QALY
(€8039/QALY) for the NHS. CONCLUSIONS: The standard use
of rhBMP-2 in ALIF surgery lowers costs for surgically treated
patients with degenerative changes of the lumbar spine in
Germany and is a cost-effective treatment option in the UK.
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OBJECTIVES: Clinical practice guidelines have been shown 
to improve medical practice. However the place of the reps to
improve compliance with guidelines initiated by state agencies
(HAS, AFSSAPS) has not been evaluated. The study has been ini-
tiated by several pharmaceutical industries involved in research.
METHODS: Two intervention studies were used to provide evi-
dence of the effectiveness of the reps visits on the physician prac-
tice. During their visit, the reps gave a written document. The
written document was a validated and synthesized version of a
guideline initiated by state agencies. The subjects of the guide-
lines were asthma or migraine. The ﬁrst intervention study eval-
uated the physicians’ perception of the reps’ intervention. The
second study evaluated the physicians’ knowledge. For the ﬁrst
study, the study material was a questionnaire (12 questions) and
the study was conducted by phone. For the second study, the
study material was an internet based questionnaire (40 ques-
tions) which follows the content of the written document given
by the reps to the physicians. A score was constructed to evalu-
ate the level of knowledge of the physicians. RESULTS: For the
ﬁrst study: 800 physicians have been included. 81% (82%) ﬁnd
the intervention of the reps useful and 76 % (81%) legitimate
the guidelines for asthma (migraine). For the second study: 294
physicians have been included. The level of knowledge was sig-
niﬁcantly higher for asthma after the reps’ visit (16.37/14.44)
and for the physician who conserved the written document. No
signiﬁcant results were found for migraine. CONCLUSION:
The reps can be another way to diffuse the clinical practice 
guidelines.
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OBJECTIVES: Inhaled corticosteroids (ICS) are the cornerstone
of asthma-treatment. Yet, adherence with ICS-treatment is very
low. Therefore, the aim of the study was to investigate adher-
ence, in terms of persistent use, with ICS and its determinants in
asthma-patients. METHODS: The PHARMO database includes,
among others, drug-dispensing and hospital discharge records
for >2 million subjects in The Netherlands. All asthma-patients
(age <35 yrs) with a ﬁrst prescription for ICS in 1999–2002 and
≥2 prescriptions in the ﬁrst year were included in the study. Per-
sistence during the ﬁrst year was deﬁned as the number of days
from start to time of ﬁrst failure to continue renewal of the initial
ICS, and ascertained based on the method of Catalan. Potential
determinants of persistence were assessed at ICS-start and one-
year before. RESULTS: The study-cohort included 5563 new
users of single ICS and 297 of ﬁxed combined ICS. Less than
10% of patients using single ICS, and 15% of patients using
ﬁxed combined ICS were persistent at one year. Increased 
persistence with single ICS was observed with type of ICS 
(budesonide), prescriber (specialist), prior use of long-acting
beta-agonists, previous hospitalization for asthma, metered-dose
inhaler, low starting dose, and once-daily dosing regimen at start.
Decreased persistence with ﬁxed combined ICS-treatment was
found in patients having high starting dose of ICS and prior use
of antibiotics. CONCLUSIONS: Persistence with ICS-treatment
for asthma in clinical practice is low for both single and ﬁxed
combined ICS-treatment. Persistence was mainly related to
patient-factors, such as severity of disease, and to treatment-
related factors, such as once-daily dosing frequency and low dose
